Identify the 100 leading drugs that are expected to be launched by 2011.
This 400-page report evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond:
--Unique sales forecasts by major product to 2010 and beyond
--100 key products assessed
--Eight key therapy areas covered
--Likelihood to launch assessment
--Unique competitor evaluation scores
--Critical and detailed appraisal of the research and development background
--Detailed background and market context
The report covers 8 key therapy areas (alimentary/metabolic, anti-infectives, cancer, cardiovascular, CNS, musculoskeletal, respiratory, vaccines) and includes unique sales forecasts by major product.
MAJOR THERAPY AREAS ANALYSED
Alimentary/Metabolic; Anti-Infectives; Cancer; Cardiovascular; CNS; Musculoskeletal; Respiratory; Vaccines
THE PHARMA MARKET IN CONTEXT
Too few novel products and an aggressive generic sector are taking their toll ... There are many prophets of doom all too ready to write off the research based pharma industry in the future.
And there is plenty on which to base such anxiety. The research-based industry must achieve a fair price in the face of greater cost control, while the burden of red tape and regulation is setting the bar high for successful product introduction. All the time the generics sector eats away at ageing and established portfolios.
It is a fair assessment to say that the industry, in the 1990s, rested too much on its laurels and successful product portfolios. For many years, too few truly novel medicines were brought to market, laying the foundations for the industry's current ills.
But that was then!
There is now considerable reason to view the future more positively; to coolly evaluate the research pipeline and to put that pipeline into its future market environment.
Pharmaceutical winners & losers
Essential analysis of 110 products that could change the face of the market. Following the analysis of eight key therapeutic categories, we have identified 100 winning drugs that we forecast to be launched by 2011. Products come from over 50 companies ranging from large pharma and specialty pharma to biopharmaceuticals and biotechnology companies.
Will they make it?
Our estimates assume products will gain approval for the indications we have forecast in the timeframe we have analysed. Regulatory demands and pressures on cost and development budgets increasingly mean safe and effective medicines are not brought to market. That is why we provide a unique assessment of their likelihood to launch.
This report is essential reading for industry planners and investors. Anyone wanting an insightful analysis of the companies and products which will shape the global pharmaceutical industry over the next 5 years need look no further than this report.
Companies and Drugs Mentioned
Acomplia (sanofi-aventis); AER x iDMS (NovoNordisk/Paradigm); Arxxant (Eli Lilly); APD356 (Arena Pharmaceuticals); AVE-0010 (sanofi-aventis); Byetta (Eli Lilly/Amylin); Exubera (Pfizer); Galida (AstraZeneca); Galvus (Novartis); Januvia (Merck & Co.); Liraglutide (Novo Nordisk); Naveglitazar (Eli Lilly); Pargluva (BMS); Saxagliptin- Metabolism (Bristol-Myers Squibb); Soraprazan (Altana); Suloxdexide (Keryx); TAK;390MR (Takeda); Viral infections; Anidulafungin (Pfizer); Aptivus (Boehringer Ingelheim); Aplaviroc (GlaxoSmithKline); Ceftobiprole (Johnson & Johnson); Garenoxicin (Schering-Plough); GW 695634 (GlaxoSmithKline); Maraviroc (Pfizer); MK;0518 (Merck & Co); Retapamulin (GlaxoSmithKline); Telbivudine (Novartis); TMC;114 (Johnson & Johnson/Tibotec Pharma); Tygacil (Wyeth); Vicriviroc (Schering-Plough); VX-950 (Vertex Pharmaceuticals); Zeven (Pfizer); Acapodene (GT x); AP23573 (ARIA D Pharmaceuticals); Dasatinib (Bristol-Myers Squibb); Ixabepilone (Bristol-Myers Squibb); Lapatinib (GlaxoSmithKline); Nexavar (Onyx Pharmaceuticals/Bayer) ; Panitumumab(Amgen/Abgenix); Revlimid (Celgene); Satraplatin(GPC Biotech/Spectrum Pharmaceutical) ; Sutent (Pfizer); Telcyta (Telik); Ticilimumab (Pfizer/Amgen) ; Vatalanib (Novartis/Schering); AGI 1067 (AtheroGenics/AstraZeneca) ; AZD7009 (IV) (AstraZeneca); BAY 59-7939 (Bayer/Johnson & Johnson); CERA (Roche/Chugai); Cerovive (AstraZeneca); Dronedarone (sanofi-aventis) ; Exjade (Novartis) ; Procoralan (Servier); Prasugrel (Eli Lilly/Sankyo) ; Ranexa (CV Therapeutics) ; Regadenoson (Astella/CV Therapeutics); Rasilez (Novartis); Revatio (Pfizer); Thelin (Encysive Pharmaceuticals); Torcetrapib/Lipitor (Pfizer); Alzhemed (Neurochem); Asenapine (Pfizer/Organon); Bifeprunox (Wyeth/Solvay/Lundbeck); Champix (Pfizer); Daytrana (Shire); DVS 233 (Wyeth); Flurizan (Myriad Genetics); Gaboxodol (Lundbeck/Merck); Indiplon (Pfizer /Neurocrine); Laquinimod (Teva/Active Biotech); Lunesta/Estorra (Sepracor); Lurasidone (Dainippon Sumitomo Pharma/Merck & Co.); Lyrica (Pfizer); Mylinax (Serono/Ivax); NS2359 (GlaxoSmithKline/NeuroSearch); Paliperidone (Johnson & Johnson); Phenserine (Axonyx); Rozerem (Takeda); Saredutant (Sanofi-Aventis); Actemra (Roche/Chugai); Bazedoxifene (Wyeth); Cimzia (UCB /Celltech) ; CNTO 148 (Johnson & Johnson/Schering-Plough); Denosumab (Amgen); Entereg (GlaxoSmithKline/Adolor); Febuxostat (TA P Pharmaceutical Products) ; Orencia (Bristol-Myers Squibb); Preos (NPS Pharmaceuticals); Alvesco (Altana/sanofi-aventis); Ariflo (GSK); Asmanex (Schering-Plough) ; Daxas (Altana); GSK 159797 (GSK /Theravance); Mepolizumab (GlaxoSmithkline); NVA237 (Novartis/Vactura/Arakis); QAB 149 (Novartis); Symbicort (AstraZeneca); Xolair (Novartis); Cervarix (GlaxoSmithKline/MedImmune); Gardasil (Merck & Co/sanofi pasteur) ; GVAX (Cell Genesys)- L-BL P25 (Biomira/Merck KG aA); Provenge (Dendreon); Rotarix (GlaxoSmithKline/Avant Immunotherapeutics); Rotateq (Merck & Co.); Streptorix (GlaxoSmithKline/MedImmune); Zostavax (Merck & Co.)
For more information visit http://www.researchandmarkets.com/reports/c37794
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 1, 2006|
|Previous Article:||BTU International Acquires AtmoPlas(TM) Technology and Research Organization from Dana Corporation.|
|Next Article:||Digital ID World To Highlight More Than 40 Real-World Deployments; Enterprise IT professionals emphasize keys to success in identity initiatives.|